Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Contract Signed with ScandiNova

22 Jul 2014 07:00

RNS Number : 9237M
Advanced Oncotherapy PLC
22 July 2014
 



22 July2014

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with ScandiNova Systems AB

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy using protons to treat cancer, announces that it has entered into a collaboration with industry leader ScandiNova Systems AB ("ScandiNova"). ScandiNova will develop the high energy systems that will power the unit of the proprietary LIGHT system which will create the proton beam.

 

ScandiNova was founded in 2001 to commercialise technical expertise in pulsed power applications including Radiotherapy, Radar, industrial X-ray and scientific accelerator systems. The company is located in Uppsala, Sweden and has established a global network of collaborations with highly skilled and experienced partners covering industry, academia and research organisations such as CERN in Europe, Lawrence Livermore and Brookhaven National Laboratories in the US.

ScandiNova specialises in the development of solid state controlled power systems which require about one third of the space and are 30% more efficient than those used in standard, older technology - synchrotrons.

Mikael Lindholm, Founder, Senior VP Sales & Marketing ScandiNova, commented: "We have been working with ADAM since 2007 and from the very start have seen the potential in the LIGHT technology which should deliver a superior proton therapy technology. Our Solid State Pulse Power products are widely used and are now installed in 28 different countries in Europe, Asia, Australia, and North and South America. For us, it is a privilege to be working with an organisation which could become the number one supplier of the next generation of proton therapy. "

 

Sanjeev Pandya, CEO of Avdanced Oncotherapy, added: "In our due diligence prior to the acquisition of the LIGHT technology, it became clear that there were already many world class partners involved in the development of the LIGHT programme. ScandiNova is one such partner and I am really pleased to be able to make this announcement. Advanced Oncotherapy is going to continue this relationship and ScandiNova will become a key partner and supplier in helping us develop our complete LIGHT system."

 

For further information contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya (CEO)

Tel: +44 20 3617 8739

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

 

Beaufort Securities (Joint Broker)

 

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

 

 

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

Mission:

To facilitate the wider use of particle therapy with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

 

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

For more information, please visit http://www.avoplc.com

 

About ScandiNova

 

ScandiNova Systems AB is a company based in Uppsala, Sweden. The company has an office in USA and representatives in 8 other countries. The company is growing continuously, since many customers in various applications are leaving the old traditional technology.

 

ScandiNova provides advanced high power Pulse Generators and fully integrated RF units, providing RF power up to 100MW and voltage pulses up to 500kV. The ScandiNova products are based on a unique patented Solid State parallel switching technology, which provides very high reliability and exceptional pulse quality and precision. Additionally, the power consumption is about 30% less than the traditional technology, which in high power applications is an important environmental requirement.

 

ScandiNova is supported by its main strong owners SEB Ventures (part of the biggest Swedish Bank SEB) and Industrifonden (the biggest government initiated fund).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTVFLFLZDFFBBQ
Date   Source Headline
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.